4th Quarter - Report

DENDREON PHARMACEUTICALS, LLC for DENDREON PHARMACEUTICALS, LLC

Firm
Client
Income
—
Expenses
$120,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Veterans VET

Prostate cancer clinical pathway H.R. 6092: The Veterans Prostate Cancer Treatment and Research Act

Foreign entity interest: Dendreon, a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.

LobbyistCovered position, as disclosed
ANDREW SAELENS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 6092 (116th)

Medical/Disease Research/Clinical Labs MED

Prostate Cancer treatment and Medicare Part B payment reform. S. 2543, the Prescription Drug Pricing Reduction Act of 2019 S. 3129/H.R. 19, the Lower Costs, More Cures Act of 2019 H.R. 748, the CARES Act. H.R.3 - Elijah E. Cummings Lower Drug Costs Now Act

Foreign entity interest: Dendreon, a subsidiary of Nanjing Xinjiekou Department Store, Co. Ltd. in China.

LobbyistCovered position, as disclosed
ANDREW SAELENS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 3 (116th), S. 2543 (116th), H.R. 19 (116th), S. 3129 (116th), H.R. 748 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.